Skip to content

Inhibrx Biosciences

US · INBX #3022 by market cap Listed 2024
68.97 -5.36 -7.21%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 73.32 -1.36%
After-hours 68.97 0.00%
126.7068.9768.972026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on INBX?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -22.0% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has risen to 23.0% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days B → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2849 U.S. stocks StockVane covers.

Last computed: 2026-11-21 14:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall D

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability F

How much profit the business keeps from each dollar of sales and capital.

Operating margin -10,386.5% Better than 1%
Net margin -10,773.5% Better than 1%
Return on equity -197.8% Better than 3%
Return on invested capital -106.5% Better than 2%
Momentum D+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -33.4% Better than 15%
6-month return -31.9% Better than 17%
12-month return (ex latest month) 15.7% Better than 54%
Distance below 52-week high 55.6% Better than 14%
Financial Health D+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 3.9x Better than 81%
Debt to assets 73.1% Better than 5%
Interest coverage -10.5x Better than 13%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 286.6% Better than 97%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -17.20%
1M -27.63%
3M -30.44%
6M -37.31%
YTD -12.70%
1Y -13.61%

Key statistics

Price & volume

Prev close
74.33
Open
72.72
Day range
68.78 - 74.60
Avg price
71.09
Volume
252.13K
Turnover
17.92M
Amplitude
7.83%
52-week range
57.30 - 155.29

Valuation

P/E
-7.63
P/E (TTM)
-7.61
P/B
-11.86
EPS
-9.04
Net profit
-133.51M
Net assets
-85.88M

Share structure

Market cap
1.02B
Float cap
557.55M
Shares out
14.77M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2024-05-28
52-week range 12% of range
57.30 155.29

55.6% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+5.60M net over the window

Short interest

Shares short
3.39M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Inhibrx Biosciences (INBX)?

Inhibrx Biosciences last traded at 68.97. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Inhibrx Biosciences's market cap?

About 1.02B.

What is the P/E ratio of Inhibrx Biosciences?

The trailing twelve-month P/E is -7.61. The Valuation tab shows it against the stock's own five-year range.

Does Inhibrx Biosciences pay a dividend?

Inhibrx Biosciences does not currently pay a regular dividend.

Is Inhibrx Biosciences a buy according to analysts?

The consensus of 3 analysts is a Buy rating, with an average 12-month price target of 266.67, which implies 286.6% upside from the current price. This is not investment advice.

What is Inhibrx Biosciences's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Inhibrx Biosciences a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Inhibrx Biosciences discussion 0 comments

Add a comment